Effects of GLP‐1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta‐analysis

AIM: To evaluate the cardiovascular outcomes of glucagon‐like peptide‐1 receptor agonists (GLP1‐RA) in patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD). MATERIALS AND METHODS: We searched PubMed, Ovid MEDLINE, CINAHL, and Web of Science databases for randomized controlled trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Michael, Lewis, Jelena, Rao, Hindu, Carter, Jessica, Portillo, Ivan, Beuttler, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review of Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099849/
https://www.ncbi.nlm.nih.gov/pubmed/36271706
http://dx.doi.org/10.1002/phar.2737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099849/
https://www.ncbi.nlm.nih.gov/pubmed/36271706
http://dx.doi.org/10.1002/phar.2737

Ejemplares similares